When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
Merve Cansu PolatElif ÇelikelZahide Ekinci TekinTuba KurtMelike Mehveş KaplanVildan GüngörerPakize Nilüfer TekgözMüge SezerCüneyt KaragölSerkan CoşkunNimet ÖnerSerdar SezerBanu Çelikel AcarPublished in: European journal of pediatrics (2024)
• Approximately one-fifth of patients with persistent oligoarticular JIA on methotrexate may require the addition of a biological disease modifying anti-rheumatic drug during follow-up. • The JADAS10 calculated at 3 and 6 months is a valuable tool to identify patients who should be added biological disease modifying anti-rheumatic drugs in persistent oligoarticular JIA.